Albumin Induced Hypercoagulability Does Not Reduce Blood Loss In Patients Undergoing Total Hip Arthroplasty

Background and Aims: Albumin may enhance and hydroxyethyl starch (HES) may impair haemostasis. While the effects are also dependent on haemodilution we minimized it by early structured transfusion therapy, and compared albumin and HES regarding blood loss and coagulation parameters in hip arthroplasty patients.

Material and Methods: 101 patients undergoing primary hip arthroplasty received in random order 4 % albumin (n = 48) or HES (average Mw 120 kDa/molar substitution ratio 0.7, n=53). The administration of colloid, red blood cell (RBC), fresh frozen plasma and platetet concentrates begun after a 6–8 %, 12–16 %, 60 % and 100 % blood loss of the patient’s calculated blood volume respectively. Explanatory risk factors for blood loss were modelled by regression analysis.

Results and Conclusions: Administration of albumin or HES 1200 ml (500–2000 and 500–1800) [median (range) respectively] did not affect blood loss. The vWF antigen was higher in the albumin group (p = 0.04) postoperatively. Haematocrit value, platelet count, bleeding time, prothrombin time value, activated thromboplastin time, FV activity and fibrinogen concentration were comparable between the groups. Long operation time was associated with great blood loss (p < 0.001). In hip arthroplasty patients with near normal levels of haematocrit albumin enhanced coagulation without altering blood loss.